Abstract
Objective
Neuroleptic malignant syndrome (NMS) is one of the most serious adverse reactions to antipsychotic medications. We accumulated data on Japanese NMS patients and, in a study designed to examine the effects of drug metabolism on the occurrence of NMS, tested the possibility of association between NMS and CYP2D6 polymorphisms.
Methods
We studied 53 patients who had experienced NMS and 112 healthy individuals. We determined what drugs the patients with NMS had been given and retrospectively identified candidates for drugs causing NMS. We screened the prevalence of CYP2D6 genotypes using polymerase chain reaction and restriction fragment length polymorphism analyses.
Results
The prevalence of *5 alleles in the group of all patients with NMS was higher than that in the controls, though this difference was not statistically significant (10.4% vs. 5.4%; P = 0.107; odds ratio (OR) 2.05; 95% confidence interval (CI) 0.87–4.80). No association was found between the frequency of *10 alleles and the occurrence of NMS. We found *4 and duplicated alleles in only one patient each among the patients with NMS. A total of 29 patients appeared to have developed NMS as a result of having taking CYP2D6 substrates. The prevalence of *5 alleles in these 29 patient was significantly higher than that in the controls (15.5% vs. 5.4%; P = 0.020; OR 3.25; 95% CI 1.30–8.13).
Conclusion
Our findings suggest that the CYP2D6*5 allele is likely to affect vulnerability to development of NMS.
Similar content being viewed by others
References
Kawanishi C (2006) Pharmacogenetic aspects of neuroleptic malignant syndrome. Curr Pharmacogenomics 4:113–119
Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77:185–202
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, and Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464–470
Caroff SN, Mann SC, Campbell EC (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 30:314–321
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464–470
Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122
Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka K (2000) Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiat Genet 10:145–147
Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of *10. Pharmacogenetics 10:567–570
Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3:201–218
Iwahashi K (1994) CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 36:780–782
Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T, Sugiyama N, Kosaka K (1998) Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 160:102–104
Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y (2005) CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report. Psychiatry Clin Neurosci 59:504–507
Pope GH, Keck PE, McElroy SL (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143:1227–1233
Kawanishi C, Hanihara T, Maruyama Y, Matsumura T, Onishi H, Inoue K, Sugiyama N, Suzuki K, Yamada Y, Kosaka K (1997) Neuroleptic malignant syndrome and hydroxylase gene mutations: No association with CYP2D6A or CYP2D6B. Psychiatr Genet 7:127–129
Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410–418
Lundqvist E, Johanson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and method for detection of duplicated CYP2D6 genes. Gene 226:327–338
Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351–355
Wennerholm A, Johansson I, Massele AY, Jande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson L (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analysis of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707–714
Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y (1977) Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 31:565–576
Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA (1989) Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46:914–918
Sachdev P, Mason C, Hadzi-Pavlovic D (1997) Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 154:1156–1158
Berardi D, Amore M, Keck PE Jr, Troia M, Dell’Atti M (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 44:748–754
Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M (1998) Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 18:349–351
Deuschl G, Oepen G, Hermle L (1987) Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 20:168–170
Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1997) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 41:1222–1224
Caroff SN, Mann SC (1998) Neuroleptic malignant syndrome. Psychopharmacol Bull 24:25–29
Wells AJ, SommiRW, Crismon L (1988) Neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 22:475–480
Lazarus AL, Moore KE, Spinner NB (1991) Recurrnt neuroleptic malignant syndrome associated with inv dup (15) and mental retardation. Clin Genet 39:65–67
Mahendran R, Winslow M, Lim D (2000) Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry 34:699–700
Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjoqvist F (2000) CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56:679–683
Ellingrod VL, Schultz SK, Arndt S (2000) Association between cytochrome P450 2D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 10:9–11
Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32:101–106
Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107–113
Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131:174–179
Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31–34
Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, Vries R, Kaneko S (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25:287–293
Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S (2003) Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacol 28:1501–1505
Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 9:293–298
Acknowledgements
This study was supported in part by a Grant-in-Aid for Scientific Research (No. 16790698) from the Ministry of Education, Science, Sports, and Culture, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kato, D., Kawanishi, C., Kishida, I. et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 63, 991–996 (2007). https://doi.org/10.1007/s00228-007-0355-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0355-8